Supplementary Figure 1.docx (60.24 kB)

Supplementary Figure 1: Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points.docx

figure

posted on 2021-11-09, 15:15 authored by Ernest Law, Roya Gavanji, Sarah WalshSarah Walsh, Anja Haltner, Rebecca McTavish, Chris Cameron

Supplementary Figure 1

Funding

Pfizer, Inc.

History

Usage metrics

Read the peer-reviewed publication

Resource title* Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points

Journal of Comparative Effectiveness Research

Categories

Cancer therapy (excl. chemotherapy and radiation therapy)

Keywords

Abemaciclib advanced breast cancer health-related quality of life HER2-negative hormone receptor-positive indirect treatment comparison matching-adjusted indirect comparison Palbociclib patient-reported outcomes quality of life Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0

Exports